Target intelligence / Profile preview

Tumor suppressor protein (TSP)

Target
TSP
Molecular classification
Transcription factor, Cell cycle regulator, DNA repair enzyme, Signal transduction inhibitor, "Gatekeeper" and "caretaker" gene products
01

Overview

Tumor suppressor proteins are a broad group of molecules encoded by tumor suppressor genes that restrain cell growth, promote apoptosis, repair DNA, and maintain genomic stability. These proteins function through a wide range of mechanisms, including acting as transcription factors, cell cycle regulators, checkpoint proteins, DNA repair enzymes, and inhibitors of signaling pathways. Their main biological role is to suppress tumor formation, and loss-of-function mutations in tumor suppressor genes are a common feature in many cancers. Tumor suppressor proteins can serve as diagnostic and prognostic biomarkers and some are targets for therapeutic intervention, mainly in strategies that restore or mimic their function. Notable examples include p53, Rb, PTEN, and BRCA1/2.

Other names
tumor suppressorsTSG protein (from "tumor suppressor gene protein")anti-oncogenes
02

Mechanism of action

Restoring wild-type function of mutated or deleted tumor suppressor proteins (e.g., p53 reactivation); Inhibiting upstream negative regulators (e.g., MDM2 inhibition to free p53); Synthetic lethality (e.g., PARP inhibition in BRCA1/2 loss).

03

Biological functions

Inhibition of cell cycle progressionPromotion of apoptosisDNA repair and genomic stabilityInhibition of mitogenic signaling and cell proliferationInhibition of angiogenesis and metastasisCell adhesion
04

Disease associations

Cancer (loss-of-function mutations drive many cancers)Inherited cancer syndromes
05

Safety considerations

Some tumor suppressor proteins act in multiple tissues and pathways; restoration or activation may have off-target or systemic effects, including potential for toxicity in normal proliferating tissuesGene therapy approaches face delivery and specificity challenges
06

Interacting drugs

MDM2 inhibitors (for p53 reactivation, e.g., nutlin-3)

2 more in the full profile.

07

Biomarkers

Loss or mutation of specific tumor suppressor proteins (e.g., p53, BRCA1/2, PTEN) as biomarkers for cancer diagnosis, prognosis, and therapy selection

Beyond the preview

Go deeper on Tumor suppressor protein (TSP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tumor suppressor protein (TSP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call